Cellanome

Cellanome is a life-science tools company developing an integrated live-cell analysis platform that links how cells look and behave over time to their molecular profiles. Its central technology, CellCage enclosures, are micro-3D-printed, biocompatible microenvironments that isolate single cells or defined ensembles while remaining permeable to media, reagents and, in some configurations, cell-cell signaling. Cells can be cultured, perturbed, imaged and then profiled by RNA sequencing within a single workflow, so that live-cell observations remain linked to end-point transcriptomic and sgRNA readouts from the same cells (sources 0, 2, 3).

The commercial product is the Cellanome R3200 Platform, comprising the R3200 instrument, flow cells, assays and reagent kits, and a cloud software suite. The instrument automates culture, reagent delivery, live-cell imaging (brightfield plus four fluorescence channels, 4X and 10X objectives), temperature control and programmable media exchange, supporting multi-day walk-away runs across tens of thousands of enclosures per flow cell. Flow cells are lane-isolated for parallel conditions, offer surface coatings (fibronectin, laminin, poly-L-ornithine) and come in imaging-only or RNA-linked formats. Assay options span fluorescence-based phenotypic and functional readouts, RNA-Seq, CRISPR-Seq and AI-based morphotyping, with perturbation by small molecules, antibodies, other treatments or CRISPR. The cloud platform handles run planning and monitoring, automatic integration of imaging and sequencing data at cell or ensemble level, code-free gating, and export in formats such as Seurat-compatible .rds files (sources 0, 3, 4).

Stated application areas are oncology, immunology, neurobiology, and aging and metabolic disease, including tumor-immune interaction studies, neuron growth and synapse formation, immune response profiling and cellular senescence. The company positions the resulting longitudinal, multimodal datasets as training data for AI and computational models of biology (sources 0, 2, 3, 4).

Founding story

Co-founder Mostafa Ronaghi is a molecular biologist and technology developer, an inventor of pyrosequencing methods for DNA sequencing and former chief technology officer of Illumina from 2008 to 2021. He describes Cellanome as a step beyond DNA sequencing toward capturing large data sets from live cells at single-cell resolution and high throughput (source 7).

Business model

Cellanome sells an integrated instrument-plus-consumables-plus-software system: the R3200 instrument, programmable flow cells, kitted reagents for RNA-Seq and CRISPR-Seq assays, and a cloud analysis platform. It also offers services including installation and hands-on training, proof-of-principle studies, workflow transition consulting, assay development and optimization, and ongoing scientific support (source 4).

Sources describe an instrument, consumable (flow cells and kitted reagents), cloud software and support/services offering, but do not disclose pricing or revenue figures (source 4).

Traction

Company materials state that researchers across academia and industry are using the platform for neuronal network, immune interaction and perturbation-response studies, and that results are presented at scientific conferences; a resource library of publications, posters, presentations and demos is maintained. No customer counts, unit placements or revenue figures are disclosed in the sources (sources 3, 5).

Latest developments

Recent public activity includes a December 2025 podcast marking the company's debut with CEO Omead Ostadan, a January 2026 podcast with Matthew Spitzer and Pier Federico Gherardini on studying cell function, a March 2026 GenomeWeb article on Cellanome showcasing its live-cell analysis platform at AGBT, and a June 2026 podcast with Gary Schroth on connecting cellular behavior to the transcriptome. The company states it is actively hiring across research, engineering and commercial teams (sources 0, 2).